Patents by Inventor Bridget WAGNER

Bridget WAGNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of histone deacetylase
    Patent number: 11377423
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 5, 2022
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • TARGETED DELIVERY TO BETA CELLS
    Publication number: 20200384115
    Abstract: The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to ?-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to ?-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in ?-cells.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 10, 2020
    Inventors: Amit CHOUDHARY, Debasish MANNA, Miseon LEE, Bridget WAGNER, Basudeb MAJI
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20180072671
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: August 16, 2017
    Publication date: March 15, 2018
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • Inhibitors of histone deacetylase
    Patent number: 9790184
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: October 17, 2017
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20150191427
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 9, 2015
    Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis
  • Combinatorial rosamine library to detect cell-state switching
    Patent number: 8951938
    Abstract: The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 10, 2015
    Assignees: New York University, President and Fellows of Harvard College
    Inventors: Young-Tae Chang, Young-Hoon Ahn, Yun Kyung Kim, Bridget Wagner, Hyman A. Carrinski, Paul Clemons, Stuart Schreiber
  • Compounds and methods for treating autoimmune diseases
    Patent number: 8741905
    Abstract: The invention relates to a compound of Formula I:
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: June 3, 2014
    Assignees: The Broad Institute, Inc., President and Fellows of Harvard College
    Inventors: Bridget Wagner, Jeremy Duvall, Danny Hung-Chieh Chou
  • COMBINATORIAL ROSAMINE LIBRARY TO DETECT CELL-STATE SWITCHING
    Publication number: 20090227467
    Abstract: The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest.
    Type: Application
    Filed: December 22, 2008
    Publication date: September 10, 2009
    Applicants: NEW YORK UNIVERSITY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Young-Tae CHANG, Young-Hoon AHN, Yun Kyung KIM, Bridget WAGNER, Hyman A. CARRINSKI, Paul CLEMONS, Stuart SCHREIBER
  • Methods and compositions for treating metabolic disorders
    Publication number: 20090143279
    Abstract: The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.
    Type: Application
    Filed: June 13, 2008
    Publication date: June 4, 2009
    Inventors: Vamsi Krishna Mootha, Bridget Wagner, Toshimori Kitami